Study Shows Rabeprazole Provides First-Dose Heartburn Relief. Part 2

The cogitation assessed affected role symptoms using a 5-point
criterion, which ranged from 0 (indicating no symptoms) to 4
(indicating severe symptoms).
On day 1, patients receiving rabeprazole achieved a change in their
statistic daytime indicant badness of more than 0.5 points on the
covering, while patients receiving medicine experienced a slight amount
in their statistic grievance.
By day 2, patients receiving rabeprazole had achieved a change of
magnitude in their ratio daytime grounds intensity of more than 0.7
points from service line, which was significantly greater than the
results seen in patients taking medicinal drug.

There was no statistically significant variation between the
responses seen in patients receiving the 20-mg dose of vs the 10-mg
dose.
Both doses were generally well-tolerated in this patient role grouping,
with adverse result rates similar across all discourse groups,
including medicinal drug.

“This
new engrossment strongly suggested that Pariet/Aciphex offered
significant evidence modification on the beginning day with the
starting time dose for patients who suffered from non-erosive ebb
disease,” said the study’s lead researcher, Philip Miner, MD,
chairperson and medical theater director of the Oklahoma Initiation for
Digestive Investigation. “By providing significant daytime and
night-time indicant amends, Pariet/Aciphex offered potentially
important benefits to these patients.

This is a part of article Study Shows Rabeprazole Provides First-Dose Heartburn Relief. Part 2 Taken from "Generic Aciphex (Rabeprazole) Review" Information Blog